Clinical Trial Update: An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) [Phase 3]

View source ↗

Summary

Completed Phase 3 open-label trial evaluating the response to adalimumab in active ankylosing spondylitis patients who have failed standard therapy or TNF inhib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED